

1        **Systematic review of genotype-stratified treatment for monogenic insulin resistance**

2

3        Robert K. Semple<sup>1,2</sup>, Kashyap A. Patel<sup>3,4</sup>, Sungyoung Auh<sup>5</sup>, ADA/EASD PMDI<sup>6</sup>, Rebecca J. Brown<sup>7</sup>

4

5        **Affiliations**

6        <sup>1</sup> Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK

7        <sup>2</sup> MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh,  
8        UK

9        <sup>3</sup> Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.

10       <sup>4</sup> Department of Diabetes and Endocrinology, Royal Devon and Exeter NHS Foundation Trust, Exeter,  
11       UK.

12       <sup>5</sup> Office of the Clinical Director, National Institute of Diabetes and Digestive and Kidney Diseases,  
13       National Institutes of Health, Bethesda, MD, USA

14       <sup>6</sup> American Diabetes Association/European Association for the Study of Diabetes Precision  
15       Medicine in Diabetes Initiative

16       <sup>7</sup> National Institute of Diabetes and Digestive and Kidney Diseases. National Institutes of Health.  
17       Bethesda, MD, USA.

18

19       **Correspondence**

20       Rebecca J. Brown, MD, MHSc

21       Building 10-CRC, Room 6-5942

22       10 Center Drive

23       Bethesda, MD 20892

24       Email: brownrebecca@niddk.nih.gov

25       Voicemail: 301-594-0609

26       Fax: 301-480-0365

27

28       **Keywords**

29       Precision Medicine, Diabetes, Genetics, Insulin Resistance, Lipodystrophy, Insulin Receptor,

30       Metreleptin, Leptin, thiazolidinediones, Insulin-like growth factor-1

31

32       **Running Title**

33       Precision Treatment of Monogenic Insulin Resistance

34

35       **Word counts** Abstract: 297 words; Main Text: 3,501 words

36 **Abstract**

37

38 **Objective:** To assess the effects of pharmacologic and/or surgical interventions in monogenic insulin  
39 resistance (IR), stratified by genetic aetiology.

40 **Design:** Systematic review.

41 **Data sources:** PubMed, MEDLINE and Embase, from 1 January 1987 to 23 June 2021.

42 **Review methods:** Studies reporting individual-level effects of pharmacologic and/or surgical  
43 interventions in monogenic IR were eligible. Individual subject data were extracted and duplicate  
44 data removed. Outcomes were analyzed for each affected gene and intervention, and in aggregate  
45 for partial, generalised and all lipodystrophy.

46 **Results:** 10 non-randomised experimental studies, 8 case series, and 21 single case reports met  
47 inclusion criteria, all rated as having moderate or serious risk of bias. Metreleptin was associated  
48 with lower triglycerides and hemoglobin A1c in aggregated lipodystrophy (n=111), in partial  
49 lipodystrophy (n=71) and generalised lipodystrophy (n=41)), and in *LMNA*, *PPARG*, *AGPAT2* or *BSCL2*  
50 subgroups (n=72,13,21 and 21 respectively). Body Mass Index (BMI) was lower after treatment in  
51 partial and generalised lipodystrophy overall, and in *LMNA* or *BSCL2*, but not *PPARG* or *AGPAT2*  
52 subgroups. Thiazolidinedione use was associated with improved hemoglobin A1c and triglycerides in  
53 aggregated lipodystrophy (n=13), improved hemoglobin A1c only in the *PPARG* subgroup (n=5), and  
54 improved triglycerides only in the *LMNA* subgroup (n=7). In *INSR*-related IR, use of rhIGF-1, alone or  
55 with IGFBP3, was associated with improved hemoglobin A1c (n=15). The small size or absence of all  
56 other genotype-treatment combinations precluded firm conclusions.

57 **Conclusions:** The evidence guiding genotype-specific treatment of monogenic IR is of low to very low  
58 quality. Metreleptin and Thiazolidinediones appear to have beneficial metabolic effects in  
59 lipodystrophy, and rhIGF-1 appears to lower hemoglobin A1c in *INSR*-related IR. For other  
60 interventions there is insufficient evidence to assess efficacy and risks either in aggregated  
61 lipodystrophy or in genetic subgroups. There is a pressing need to improve the evidence base for  
62 management of monogenic IR.

63

## 64 **Introduction**

65           Diabetes caused by single gene changes is highly heterogeneous in molecular  
66 aetiopathogenesis. It may be grouped into disorders featuring primary failure of insulin  
67 secretion, and disorders in which insulin resistance (IR), often severe, predates secondary  
68 failure of insulin secretion and diabetes. Monogenic IR is itself heterogeneous,  
69 encompassing primary lipodystrophy syndromes, primary disorders of insulin signalling, and  
70 a group of conditions in which severe IR is part of a more complex developmental syndrome  
71 <sup>1</sup>.

72           Monogenic IR is rare but underdiagnosed. The commonest subgroup is formed by  
73 genetic lipodystrophy syndromes <sup>2,3</sup>. Recent analysis of a large clinical care cohort  
74 unselected for metabolic disease suggested a clinical prevalence of lipodystrophy of around  
75 1 in 20,000, with a prevalence of plausible lipodystrophy-causing genetic variants of around  
76 1 in 7,000 <sup>4</sup>. Monogenic IR is important to recognise, because affected patients are at risk  
77 not only of micro- and macrovascular complications of diabetes, but also of complications  
78 such as dyslipidemia, pancreatitis, and steatohepatitis, especially in lipodystrophy  
79 syndromes <sup>5</sup>. Non-metabolic complications specific to individual gene defects may also  
80 occur, including hypertrophic cardiomyopathy and other manifestations of soft tissue  
81 overgrowth <sup>3</sup>. Diabetes is also commonly the sentinel presentation of a multisystem  
82 disorder, and recognition of complex syndromes in a diabetes clinic may trigger definitive  
83 diagnostic testing.

84           The only therapy licensed specifically for monogenic IR is recombinant human  
85 methionyl leptin (metreleptin), with licensed indications encompassing a subset of patients  
86 with lipodystrophy and inadequate metabolic control <sup>6,7</sup>. The current license in the USA is

87 restricted to generalised lipodystrophy, but in Europe it extends to some patients with  
88 partial lipodystrophy. A significant proportion of the body of evidence considered in  
89 licensing addressed patients ascertained by presence of clinical lipodystrophy, and the role  
90 of genetic stratification in precision treatment of lipodystrophy has not been systematically  
91 addressed. Many other medications and other treatment options are also widely used in  
92 monogenic IR, although not licensed for that specific subgroup. Such use draws on the  
93 evidence base and treatment algorithms developed for type 2 diabetes. Several forms of  
94 monogenic IR have molecular and/or clinical attributes that suggest potential precision  
95 approaches to treatment.

96 We sought now to undertake a systematic review of the current evidence guiding  
97 treatment of monogenic IR stratified by genetic aetiology, to assess evidence for differential  
98 responses to currently used therapies, to establish gaps in evidence, and to inform future  
99 studies. This systematic review is written on behalf of the American Diabetes Association  
100 (ADA)/European Association for the Study of Diabetes (EASD) *Precision Medicine in Diabetes*  
101 *Initiative* (PMDI) as part of a comprehensive evidence evaluation in support of the  
102 2<sup>nd</sup> International Consensus Report on Precision Diabetes Medicine [Tobias et al, Nat Med].  
103 The PMDI was established in 2018 by the ADA in partnership with the EASD to address the  
104 burgeoning need for better diabetes prevention and care through precision medicine <sup>8</sup>.

105

## 106 **Methods**

### 107 *Inclusion Criteria and Search Methodology*

108 To assess treatment of severe IR of known monogenic aetiology, with or without  
109 diabetes mellitus, including generalised and partial lipodystrophy and genetic disorders of

110 the insulin receptor, we developed, registered and followed a protocol for a systematic  
111 review (Prospero ID [CRD42021265365](https://doi.org/10.1101/2023.04.17.23288671); registered July 21, 2021)<sup>9</sup>. The study was reported in  
112 accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis  
113 (PRISMA) guidelines. Filtering and selection of studies for data extraction were recorded  
114 using the Covidence platform (<https://www.covidence.org>, Melbourne, Australia).

115 We searched PubMed, MEDLINE and Embase from 1987 (the year before  
116 identification of the first monogenic aetiology of IR) to June 23, 2021 for potentially relevant  
117 human studies in English. We used broad search terms designed to capture the  
118 heterogeneity of monogenic IR and its treatments. We searched for studies addressing 1.  
119 Severe IR due to variant(s) in a single gene OR 2. Congenital generalised or familial partial  
120 lipodystrophy due to variant(s) in a single gene. We selected only studies that reported a  
121 treatment term, including but not limited to mention of 1. Thiazolidinediones (TZD), 2.  
122 Metreleptin, 3. SGLT2 inhibitors, 4. GLP-1 analogues, 5. Bariatric surgery (all types), 6.  
123 Recombinant human IGF-1 or IGF-1/IGFBP3 composite, 7. U-500 insulin. No interventions  
124 were excluded in the primary search. In addition to the automated search, we hand  
125 searched reference lists of relevant review articles. Given the rarity of monogenic IR, no  
126 study types were excluded in the initial search. We ultimately considered experimental  
127 studies, case reports, and case series. The full search strategy is described in Supplemental  
128 Table 1.

129 Study selection for data extraction was performed in two phases, namely primary  
130 screening of title and abstract, then full text review of potentially eligible articles. Two  
131 authors independently evaluated eligibility, with discrepancies resolved by a third  
132 investigator. We excluded publications without original data, such as reviews, editorials, and  
133 comments, and those solely addressing severe IR or lipodystrophy of unknown or known

134 non-monogenic aetiology, including HIV-related or other acquired lipodystrophies, or  
135 autoimmune insulin receptoropathy (Type B insulin resistance). Studies in which no clear  
136 categorical or numerical outcome of an intervention was reported, or in which interventions  
137 were administered for less than 28 days were also excluded.

#### 138 *Data extraction and outcome assessments*

139 One author extracted data from each eligible study using data extraction sheets.  
140 Data from each study was verified by all 3 authors to reach consensus. Data were extracted  
141 from text, tables, or figures. Study investigators were contacted for pertinent unreported  
142 data or additional details where possible, most commonly genetic aetiology of insulin  
143 resistance in reported patients, and outcome data.

144 Data extracted for each study included first author, publication year, country, details  
145 of intervention, duration of follow-up, study design, and number of participants. Subject-  
146 level data were extracted for outcomes of interest, including sex, genetic cause of severe  
147 insulin resistance (gene name, mono- vs biallelic *INSR* pathogenic variant), phenotypic  
148 details of severe IR/lipodystrophic subtype (generalised vs partial lipodystrophy; associated  
149 syndromic features). Subject level outcome data for were extracted prior to and after the  
150 longest-reported exposure to the intervention of interest for hemoglobin A1c (A1c), body  
151 mass index, serum triglyceride, ALT, or AST concentration, any index of liver size or lipid  
152 content, and total daily insulin dose. Potential adverse effects of interventions were  
153 recorded, including urinary tract infection, genital candidiasis, hypoglycemia, excessive  
154 weight loss, pancreatitis, soft tissue overgrowth, and tumor formation.

155

#### 156 *Risk of bias and certainty of evidence assessment*

157 Quality of extracted case reports and case series was assessed using NIH Study  
158 Quality Assessment Tools<sup>10</sup>. Grading of overall evidence for specific research questions was  
159 undertaken as detailed in<sup>11</sup>.

160

### 161 *Data synthesis and analysis*

162 Extracted data were managed using Covidence and analysed with SAS version 9.4.  
163 Pooled analysis was undertaken for all combinations of genotype and intervention for which  
164 sufficient numbers were reported, as well as for aggregated lipodystrophies, and  
165 generalized and partial subgroups of lipodystrophy. Generalized Estimating Equation  
166 models were used with time as a fixed factor and study as a random factor to examine  
167 treatment effects. Serum triglyceride concentrations were analyzed with and without log  
168 transformation. Data were summarized using estimated least-squared means with  
169 corresponding 95% confidence intervals.

170

## 171 **Results**

### 172 **Identification of eligible studies**

173 Initial searching identified 2,933 studies, to which 109 were added from the  
174 bibliography of a recent comprehensive review of monogenic lipodystrophy<sup>2</sup>. 248 articles  
175 remained after screening of titles and abstracts, and 42 after full text screening (Figure 1).

176

### 177 **Included studies addressed limited interventions and most had a high risk of bias**

178 The 42 studies analysed, and assessment of their quality are summarised in Table 1  
179 and detailed in Supplemental Table 2. Study quality was assessed as being fair in 15 cases  
180 and poor in 27 cases, including all case reports. This was primarily due to high risk of bias,

181 particularly related to lack of control group for all studies. Three of the 42 studies included  
182 in further analysis included only individuals already described in other reports and were  
183 discarded, leaving 39 studies for final analysis. These comprised 10 non-controlled  
184 experimental studies, 8 case series and 21 individual case reports (Table 1). No controlled  
185 trials were found. Individuals reported in the studies included 90 with partial lipodystrophy  
186 (72 due to *LMNA* mutation and 15 due to *PPARG* mutation), 42 with generalized  
187 lipodystrophy (21 *AGPAT2*, 21 *BSCL2*, 2 *LMNA*), and 17 with IR due to *INSR* mutation(s).  
188 Among the interventions described, only the responses to metreleptin (111 recipients),  
189 thiazolidinediones (13 recipients) and rhIGF-1 (alone or as a composite with IGFBP3) (15  
190 recipients) were described in more than 5 cases (Table 1). This meant that for the large  
191 preponderance of possible genotype-treatment combinations no specific data were  
192 recovered (Supplemental Table 3). Full outcome data extracted are summarised in  
193 Supplemental Table 4, and subject-level data are shown in Supplemental Figures 1 through  
194 8.

195

#### 196 **Metreleptin treatment was associated with improved metabolic control in lipodystrophy**

197 In our registered systematic review plan we posed several subquestions about  
198 treatment of monogenic IR subtypes that we felt were tractable. The first related to the  
199 risks and benefits (assessed by side effects, A1c, serum triglyceride concentration, body  
200 mass index (BMI), and indices of fatty liver) of metreleptin in patients with different  
201 monogenic subtypes of lipodystrophy. The response to metreleptin was described in 111  
202 people (71 with partial lipodystrophy, 40 with generalized lipodystrophy)<sup>12-22</sup>. Metreleptin  
203 was administered for 19±20 months (median 12, range 1-108) and was associated with  
204 lowering of A1c in aggregated lipodystrophy, in generalized and partial subgroups, and in all



205 genetic subgroups for whom sufficient patients were reported, namely those with *LMNA*,  
206 *PPARG*, *AGPAT2* and *BSCL2* mutations (0.5 to 1.5% least square mean reduction) (Level 3  
207 evidence, Supplemental Table 4, Figure 2). Metreleptin treatment was also associated with  
208 lowering of serum triglyceride concentration in aggregated lipodystrophy, in generalized  
209 and partial subgroups, and in those with *LMNA*, *PPARG*, *AGPAT2* and *BSCL2* mutations (92 to  
210 1760 mg/dL least square mean reduction for analyses of untransformed data) (Level 3  
211 evidence, Supplemental Table 4, Figure 2). BMI was lower after treatment in aggregated  
212 lipodystrophy, in generalized and partial subgroups, and in those with *LMNA* or *BSCL2*  
213 mutations, but not *PPARG* or *AGPAT2* mutations (Level 3 evidence, Supplemental Table 4,  
214 Figure 2). Liver outcomes reported were too heterogeneous to analyse in aggregate. Only a  
215 single adverse event, namely hypoglycemia, was reported.

216

### 217 **Thiazolidinedione treatment showed variable efficacy in limited studies**

218 We next addressed the evidence of risks and benefits of thiazolidinediones (TZDs) in  
219 patients with lipodystrophy. We were specifically interested in any evidence of a greater or  
220 lesser response in partial lipodystrophy caused by *PPARG* variants than in other  
221 lipodystrophy subtypes, as TZDs are potent ligands for the gene product of the *PPARG* gene,  
222 the master regulator of adipocyte differentiation. The response to TZDs was described in  
223 only 13 people, however (12 FPLD, 1 CGL) <sup>23-32</sup>. TZDs were administered for 29±28 months  
224 (median 24, range 2-96). TZD use was associated with improved A1c in aggregated  
225 lipodystrophy (least square mean reduction 2.2%) and in *PPARG*-related but not *LMNA*-  
226 related partial lipodystrophy (Level 4 evidence, Supplemental Table 4, Figure 3). Serum  
227 triglyceride concentration decreased in aggregated lipodystrophy and in those with *LMNA*-

228 related but not *PPARG*-related partial lipodystrophy (Level 4 evidence, Supplemental Table  
229 4, Figure 3). No adverse events were reported.

230

### 231 **rhIGF-1 treatment in *INSR*-related IR was associated with improvement in A1c**

232 Our last specific question related to the risks (e.g. tumors, hypoglycemia, cardiac  
233 hypertrophy, other soft tissue overgrowth) and benefits (assessed by A1c) of recombinant  
234 human IGF-1 (rhIGF-1) or IGF-1/IGFBP3 composite in patients with pathogenic *INSR* variants.  
235 The response to rhIGF-1 was described in 15 people with pathogenic *INSR* variants for a  
236 mean of 50±86 months (median 12, range 1-288)<sup>33-42</sup>. In *INSR*-related IR, we found that use  
237 of rhIGF-1, alone or as a composite with IGFBP3, was associated with improvement in A1c,  
238 and this was true also in subgroups with monoallelic and biallelic variants (1 to 2% least  
239 square mean reduction, Level 4 evidence, Supplemental Table 4, Figure 4). One instance of  
240 increased soft tissue overgrowth and two episodes of hypoglycemia was reported.

241

### 242 **Many questions about genotype-stratified treatment were not addressed**

243 While many other interesting and clinically relevant questions arise about other  
244 potential genotype-specific responses to therapy in monogenic IR, the small size or absence  
245 of other genotype by treatment groups precluded the drawing of conclusions about risks  
246 and benefits, including for very widely used medications such as metformin<sup>25,43-45</sup>, newer  
247 agents commonly used in type 2 diabetes including SGLT2 inhibitors<sup>46,47</sup> and GLP1 agonists,  
248 and non pharmacologic interventions such as bariatric surgery<sup>48-50</sup>.

249

## 250 **Discussion**

251           Thirty-five years since *INSR* mutations were identified in extreme IR<sup>51,52</sup>, and 23  
252   years since the first monogenic cause of lipodystrophy was reported<sup>53</sup>, many different  
253   forms of monogenic IR are known<sup>1-3,54</sup>. These are associated with substantial early  
254   morbidity and mortality, ranging from death in infancy to accelerated complications of  
255   diabetes and fatty liver disease in adulthood, depending on the genetic subtype. Several  
256   opportunities for genotype-guided, targeted treatment are suggested by the causal genes,  
257   and so we set out to review the current evidence guiding treatment of monogenic IR  
258   stratified by genetic aetiology. We found a paucity of high-quality evidence (all level 3 to 4).  
259   No controlled trials of any intervention were identified, and there was substantial  
260   heterogeneity of study populations and intervention regimens, even for the same  
261   interventional agent.

262           The evidence which we did find, from a small number of uncontrolled experimental  
263   studies, augmented by case series and numerous case reports, suggest that metreleptin  
264   offers metabolic benefits across different lipodystrophy subtypes, in keeping with its  
265   licensing for use in some patients with lipodystrophy in both Europe and the USA. Notably,  
266   the evidence base considered by licensing authorities was larger than the one we present,  
267   including many studies of phenotypically ascertained lipodystrophy that included acquired  
268   or idiopathic disease. In contrast we have addressed solely individuals with lipodystrophy  
269   caused by variation in a single gene. The limited data we identified do not clearly support  
270   differential effects among different monogenic lipodystrophy subgroups, but for many  
271   subtypes numbers reported are very small. Moreover although responses appear  
272   comparable for partial and generalised lipodystrophy, this is highly likely to reflect selection  
273   bias in studies of partial lipodystrophy towards those with more severe metabolic  
274   complications and lower baseline serum leptin concentrations.

275 A clear opportunity for precision diabetes therapy in monogenic IR is offered by the  
276 IR and lipodystrophy caused by mutations in *PPARG*, which encodes the target for  
277 thiazolidinediones (TZDs) such as pioglitazone<sup>55,56</sup>. *PPARG* is a nuclear receptor that serves  
278 as the master transcriptional driver of adipocyte differentiation, and so as soon as *PPARG*  
279 mutations were identified to cause severe IR, there was interest in the potential of TZDs as  
280 specific treatments. Although we found small scale evidence supporting greater A1c  
281 reduction with TZDs in *PPARG* vs *LMNA*-related lipodystrophy, only 5 patients with *PPARG*-  
282 related lipodystrophy in whom TZD effects were clearly described were reported, and  
283 responses were inconsistent. Thus, it remains unclear whether people with IR due to *PPARG*  
284 variants are more or indeed less sensitive to TZDs than people with other forms of  
285 lipodystrophy. Loss-of-function *PPARG* mutations are the second commonest cause of  
286 familial partial lipodystrophy<sup>2</sup>, and the function of coding missense variants in *PPARG* has  
287 been assayed systematically to accelerate genetic diagnosis<sup>57</sup>, so the opportunity to test  
288 genotype-related therapy in *PPARG*-related IR seems particularly tractable in future.

289 Other obvious questions about targeted treatment of monogenic, lipodystrophic IR  
290 are not addressed by current evidence. Important examples relate to the risks and benefits  
291 of treatments used in type 2 diabetes such as GLP-1 agonists and SGLT2 inhibitors. It is  
292 rational to suppose that these medications, which decrease weight as well as improving  
293 glycaemia in those with raised BMI and diabetes, may also be efficacious in lipodystrophy  
294 even where BMI is normal or only slightly raised. This is because in both situations adipose  
295 storage capacity is exceeded, leading to “fat failure”. It is the offloading of overloaded  
296 adipose tissue, rather than the baseline BMI/adipose mass, which underlies the efficacy of  
297 therapy. However GLP-1 agonists are contraindicated in those with prior pancreatitis, while  
298 SGLT2 inhibitor use can be complicated by diabetic ketoacidosis. In untreated lipodystrophy

299 pancreatitis is common, yet this is due to hypertriglyceridaemia, which is likely to be  
300 improved by GLP-1 agonist use, while excessive supply of free fatty acids to the liver may  
301 promote ketogenesis. Thus assessment of both classes of drug in lipodystrophy and its  
302 genetic subgroups will be important to quantify risks and benefits, which may be distinct to  
303 those in obesity-related diabetes.

304         A further question we prespecified related to the use of rhIGF1 in people with severe  
305 IR due to *INSR* mutations. This use of rhIGF-1 was first described in recessive *INSR* defects in  
306 the early 1990s <sup>42</sup>, based on the rationale that IGF-1 activates a receptor and signalling  
307 pathway very closely similar to those activated by insulin. Based on case reports, case series  
308 and narrative reviews, rhIGF-1 is now commonly used in neonates with extreme IR due to  
309 biallelic *INSR* mutations, although, unlike metreleptin in lipodystrophy, this use is still  
310 unlicensed. Our review of published data is consistent with glycaemic benefits of rhIGF-1,  
311 alone or in composite form with its binding protein IGFBP3, in *INSR* mutations.  
312 Nevertheless, such studies are challenging to interpret and are potentially fraught with bias  
313 of different types, particularly publication bias favouring positive outcomes. Responses to  
314 rhIGF1 are also challenging to determine in uncontrolled studies as small differences in  
315 residual function of mutated receptors can have substantial effects on the severity and  
316 natural history of the resulting IR, yet relatively few *INSR* mutations have been studied  
317 functionally. This underlines the narrow nature of, and significant residual uncertainty in,  
318 the evidence base for use of rhIGF-1 in monogenic IR.

319         There are several reasons why important questions about precision treatment of  
320 monogenic IR have not been settled. Although severe autosomal recessive IR is usually  
321 detected in infancy, commoner dominant forms of monogenic IR are often diagnosed  
322 relatively late, often only after years of management based on presumptive diagnoses of

323 type 2 or sometimes type 1 diabetes. Initial management as type 2 diabetes means that by  
324 the time a clinical and then genetic diagnosis is made, most patients have been treated with  
325 agents such as metformin, and increasingly SGLT2 inhibitors or GLP-1 agonists, outside trial  
326 settings. It is not clear that harm is caused by such use of drugs with well-established safety  
327 profiles and efficacy in type 2 diabetes, but the lack of systematic data gathering precludes  
328 identification of specific drug-genotype interactions. Moreover, because attempts to gather  
329 evidence for monogenic IR treatment has tended to focus on high-cost adjunctive therapies  
330 such as metreleptin, the evidence base for their use is better developed, although  
331 controlled trials are lacking. Licensing of high-cost treatments such as metreleptin in  
332 lipodystrophy, while effects of many more commonly used, cheaper drugs with well-  
333 established safety profiles lack formal testing in monogenic IR is potentially problematic,  
334 skewing incentives and guidelines towards expensive therapy before optimal treatment  
335 algorithms have been established.

336 Other challenges in conducting trials in monogenic IR arise from the exquisite  
337 sensitivity of IR to exacerbating factors such as puberty, diet, and energy balance. This  
338 creates a “signal to noise” problem particularly problematic in uncontrolled studies, in  
339 which non-pharmacological components of interventions such as increased support for  
340 behavioural change may confound attribution of beneficial outcomes to pharmacological  
341 agents tested.

342 The key question now is how the evidence base for managing monogenic severe IR  
343 can be improved in the face of constraints in studying rare, clinically heterogeneous, and  
344 geographically dispersed patients who are often diagnosed late with a condition that is  
345 exquisitely environmentally sensitive. Growing interest in and development of  
346 methodologies for clinical trials in rare disease<sup>58</sup>, including Bayesian methodologies<sup>59,60</sup>,

347 and hybrid single- and multi-site designs<sup>61</sup> offer hope for future filling of evidence gaps. One  
348 important and pragmatic opportunity arises from the development of large regional,  
349 national and international networks and registries for lipodystrophy (e.g. the Europe-based  
350 ECLip registry<sup>62</sup>), allied to emergence of randomised registry-based trial (RRT) methodology  
351<sup>63,64</sup>. RRTs have attracted increasing interest in several disease areas and are particularly  
352 suitable for evaluation of agents with well-established safety profiles. When a simple  
353 randomisation tool is deployed in the context of a registry, RRTs can offer rapid, cost-  
354 effective recruitment and high external validity (i.e. relevance to “real world” practice). In  
355 monogenic IR this would permit questions to be addressed about optimal usage of different  
356 “common” medications in different genetic subgroups, including the order of introduction  
357 of therapies, and their optimal combinations. The quality of such studies will critically rely  
358 on good registry design and quality and completeness of data capture<sup>63,64</sup>.

359 In summary, severe monogenic IR syndromes are clinically and genetically  
360 heterogeneous, with high early morbidity and mortality. However despite opportunities for  
361 targeted therapy of some monogenic subgroups based on the nature of the causal gene  
362 alteration, the evidence for genotype-stratified therapy is weak. This is in part because of  
363 the rarity and frequent late diagnosis of monogenic IR, but also because therapeutic  
364 research to date has focused largely on phenotypically ascertained cross cutting diagnoses  
365 such as lipodystrophy. We suggest that approaches such as RRTs hold the best hope to  
366 answer some of the persisting major questions about precision treatment in monogenic IR.

367

368 **Authors’ declaration of personal interests**

369 R.K.S. has received speaker fees from Eli Lilly, Novo Nordisk, and Amryt. R. J. B. has received  
370 research support from Amryt, Third Rock Ventures, Ionis, and Regeneron. K.A.P. and S.A.  
371 report no conflicts of interest.

372

### 373 **Acknowledgements**

374 This research was funded in part, by the Wellcome Trust [Grant WT 210752 to RKS and WT  
375 219606 to KAP]. For the purpose of open access, the author has applied a CC0 Public  
376 Domain Dedication to any Author Accepted Manuscript version arising from this submission.  
377 RJB and SA are supported by the intramural research program of the National Institute of  
378 Diabetes and Digestive and Kidney Diseases. The ADA/EASD Precision Diabetes Medicine  
379 Initiative, within which this work was conducted, has received the following support: The  
380 Covidence license was funded by Lund University (Sweden) for which technical support was  
381 provided by Maria Björklund and Krister Aronsson (Faculty of Medicine Library, Lund  
382 University, Sweden). Administrative support was provided by Lund University (Malmö,  
383 Sweden), University of Chicago (IL, USA), and the American Diabetes Association  
384 (Washington D.C., USA). The Novo Nordisk Foundation (Hellerup, Denmark) provided grant  
385 support for in-person writing group meetings (PI: L Phillipson, University of Chicago, IL).



## 386 References

- 387 1 Bonnefond, A. & Semple, R. K. Achievements, prospects and challenges in precision care for  
388 monogenic insulin-deficient and insulin-resistant diabetes. *Diabetologia* **65**, 1782-1795 (2022).  
389 <https://doi.org/10.1007/s00125-022-05720-7>
- 390 2 Lim, K., Haider, A., Adams, C., Sleight, A. & Savage, D. B. Lipodystrophy: a paradigm for  
391 understanding the consequences of "overloading" adipose tissue. *Physiol Rev* **101**, 907-993  
392 (2021). <https://doi.org/10.1152/physrev.00032.2020>
- 393 3 Semple, R. K., Savage, D. B., Cochran, E. K., Gorden, P. & O'Rahilly, S. Genetic syndromes of severe  
394 insulin resistance. *Endocr Rev* **32**, 498-514 (2011). <https://doi.org/10.1210/er.2010-0020>
- 395 4 Gonzaga-Jauregui, C. *et al.* Clinical and Molecular Prevalence of Lipodystrophy in an  
396 Unascertained Large Clinical Care Cohort. *Diabetes* **69**, 249-258 (2020).  
397 <https://doi.org/10.2337/db19-0447>
- 398 5 Brown, R. J. *et al.* The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society  
399 Practice Guideline. *J Clin Endocrinol Metab* **101**, 4500-4511 (2016).  
400 <https://doi.org/10.1210/jc.2016-2466>
- 401 6 29 (2013).
- 402 7 Agency, E. M. *Myalepta*  
403 <[https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta#authorisation-details-](https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta#authorisation-details-section)  
404 [section](https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta#authorisation-details-section)> (2018).
- 405 8 Nolan, J. J. *et al.* ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective  
406 and Future Vision for Precision Medicine in Diabetes. *Diabetes Care* **45**, 261-266 (2022).  
407 <https://doi.org/10.2337/dc21-2216>
- 408 9 (2021).
- 409 10 *Study Quality Assessment Tools*, <[https://www.nhlbi.nih.gov/health-topics/study-quality-](https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools)  
410 [assessment-tools](https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools)> (
- 411 11 Sherifali, D. *et al.* Methods. *Canadian journal of diabetes* **42**, S6-S9 (2018).  
412 <https://doi.org/10.1016/j.jcjd.2017.10.002>
- 413 12 Musso, C., Major, M. L., Andres, E. & Simha, V. Metreleptin Treatment in Three Patients with  
414 Generalized Lipodystrophy. *Clinical medicine insights. Case reports* **9**, 123-127 (2016).  
415 <https://doi.org/10.4137/CCRRep.S40196>
- 416 13 Beltrand, J. *et al.* Resistance to leptin-replacement therapy in Berardinelli-Seip congenital  
417 lipodystrophy: an immunological origin. *Eur J Endocrinol* **162**, 1083-1091 (2010).  
418 <https://doi.org/10.1530/eje-09-1027>
- 419 14 Vatieer, C. *et al.* Adherence with metreleptin therapy and health self-perception in patients with  
420 lipodystrophic syndromes. *Orphanet J Rare Dis* **14**, 177 (2019). [https://doi.org/10.1186/s13023-](https://doi.org/10.1186/s13023-019-1141-2)  
421 [019-1141-2](https://doi.org/10.1186/s13023-019-1141-2)
- 422 15 Beltrand, J. *et al.* Metabolic correction induced by leptin replacement treatment in young  
423 children with Berardinelli-Seip congenital lipoatrophy. *Pediatrics* **120**, e291-296 (2007).  
424 <https://doi.org/10.1542/peds.2006-3165>
- 425 16 Chong, A. Y., Lupsa, B. C., Cochran, E. K. & Gorden, P. Efficacy of leptin therapy in the different  
426 forms of human lipodystrophy. *Diabetologia* **53**, 27-35 (2010). [https://doi.org/10.1007/s00125-](https://doi.org/10.1007/s00125-009-1502-9)  
427 [009-1502-9](https://doi.org/10.1007/s00125-009-1502-9)
- 428 17 Maeda, M., Maeda, T., Ebihara, K. & Ihara, K. The long-term management of congenital  
429 generalized lipodystrophy (Berardinelli-Seip syndrome): the clinical manifestations of Japanese  
430 siblings for approximately 20 years. *Clinical pediatric endocrinology : case reports and clinical*  
431 *investigations : official journal of the Japanese Society for Pediatric Endocrinology* **28**, 139-145  
432 (2019). <https://doi.org/10.1297/cpe.28.139>
- 433 18 Ebihara, K. *et al.* Efficacy and safety of leptin-replacement therapy and possible mechanisms of  
434 leptin actions in patients with generalized lipodystrophy. *J Clin Endocrinol Metab* **92**, 532-541  
435 (2007). <https://doi.org/10.1210/jc.2006-1546>

- 436 19 Ajluni, N., Dar, M., Xu, J., Neidert, A. H. & Oral, E. A. Efficacy and Safety of Metreleptin in Patients  
437 with Partial Lipodystrophy: Lessons from an Expanded Access Program. *Journal of diabetes &*  
438 *metabolism* **7** (2016). <https://doi.org:10.4172/2155-6156.1000659>
- 439 20 Sekizkardes, H., Cochran, E., Malandrino, N., Garg, A. & Brown, R. J. Efficacy of Metreleptin  
440 Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants. *J Clin*  
441 *Endocrinol Metab* **104**, 3068-3076 (2019). <https://doi.org:10.1210/jc.2018-02787>
- 442 21 Simha, V. *et al.* Comparison of efficacy and safety of leptin replacement therapy in moderately  
443 and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. *J*  
444 *Clin Endocrinol Metab* **97**, 785-792 (2012). <https://doi.org:10.1210/jc.2011-2229>
- 445 22 Takeyari, S. *et al.* Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a  
446 case report. *Clinical pediatric endocrinology : case reports and clinical investigations : official*  
447 *journal of the Japanese Society for Pediatric Endocrinology* **28**, 1-7 (2019).  
448 <https://doi.org:10.1297/cpe.28.1>
- 449 23 Chaves, C., Chaves, M., Anselmo, J. & César, R. Successful long-term use of pioglitazone in  
450 Berardinelli-Seip lipodystrophy-associated diabetes. *Endocrinol Diabetes Metab Case Rep* **2021**  
451 (2021). <https://doi.org:10.1530/edm-20-0183>
- 452 24 Collet-Gaudillat, C., Billon-Bancel, A. & Beressi, J. P. Long-term improvement of metabolic control  
453 with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case  
454 report. *Diabetes Metab* **35**, 151-154 (2009). <https://doi.org:10.1016/j.diabet.2009.01.001>
- 455 25 Gambineri, A. *et al.* Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C  
456 gene is sensitive to thiazolidinediones but not to metformin. *Eur J Endocrinol* **159**, 347-353  
457 (2008). <https://doi.org:10.1530/eje-08-0272>
- 458 26 Moreau, F. *et al.* Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a  
459 case report. *Diabetes Metab* **33**, 385-389 (2007). <https://doi.org:10.1016/j.diabet.2007.04.005>
- 460 27 Owen, K. R., Donohoe, M., Ellard, S. & Hattersley, A. T. Response to treatment with rosiglitazone  
461 in familial partial lipodystrophy due to a mutation in the LMNA gene. *Diabet Med* **20**, 823-827  
462 (2003). <https://doi.org:10.1046/j.1464-5491.2003.01034.x>
- 463 28 Simha, V., Rao, S. & Garg, A. Prolonged thiazolidinedione therapy does not reverse fat loss in  
464 patients with familial partial lipodystrophy, Dunnigan variety. *Diabetes Obes Metab* **10**, 1275-  
465 1276 (2008). <https://doi.org:10.1111/j.1463-1326.2008.00978.x>
- 466 29 Luedtke, A. *et al.* Thiazolidinedione response in familial lipodystrophy patients with LMNA  
467 mutations: a case series. *Horm Metab Res* **44**, 306-311 (2012). <https://doi.org:10.1055/s-0031-1301284>
- 468
- 469 30 Agostini, M. *et al.* A Pharmacogenetic Approach to the Treatment of Patients With PPARG  
470 Mutations. *Diabetes* **67**, 1086-1092 (2018). <https://doi.org:10.2337/db17-1236>
- 471 31 Francis, G. A. *et al.* Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian  
472 kindred with familial partial lipodystrophy type 3 (FPLD3). *BMC Med Genet* **7**, 3 (2006).  
473 <https://doi.org:10.1186/1471-2350-7-3>
- 474 32 Savage, D. B. *et al.* Human metabolic syndrome resulting from dominant-negative mutations in  
475 the nuclear receptor peroxisome proliferator-activated receptor-gamma. *Diabetes* **52**, 910-917  
476 (2003). <https://doi.org:10.2337/diabetes.52.4.910>
- 477 33 Hashimoto, N. *et al.* A case of type A insulin resistance associated with heterozygous Asn462Ser  
478 mutation of the insulin receptor gene. *Diabetology International* **3**, 239-243 (2012).  
479 <https://doi.org:10.1007/s13340-012-0079-6>
- 480 34 Jo, W. *et al.* Development of endometrial carcinoma in a patient with leprechaunism (donohue  
481 syndrome). *Clinical pediatric endocrinology : case reports and clinical investigations : official*  
482 *journal of the Japanese Society for Pediatric Endocrinology* **22**, 33-38 (2013).  
483 <https://doi.org:10.1292/cpe.22.33>
- 484 35 Perge, K. *et al.* Intrauterine Growth Restriction and Hypertrophic Cardiomyopathy as Prenatal  
485 Ultrasound Findings in a Case of Leprechaunism. *Mol Syndromol* **11**, 223-227 (2020).  
486 <https://doi.org:10.1159/000509837>

- 487 36 Plamper, M., Gohlke, B., Schreiner, F. & Woelfle, J. Mecasermin in Insulin Receptor-Related  
488 Severe Insulin Resistance Syndromes: Case Report and Review of the Literature. *International*  
489 *journal of molecular sciences* **19** (2018). <https://doi.org/10.3390/ijms19051268>
- 490 37 Carmody, D., Ladsaria, S. S., Buikema, R. K., Semple, R. K. & Greeley, S. A. Successful rhIGF1  
491 treatment for over 5 years in a patient with severe insulin resistance due to homozygous insulin  
492 receptor mutation. *Diabet Med* **33**, e8-e12 (2016). <https://doi.org/10.1111/dme.12884>
- 493 38 de Kerdanet, M. *et al.* Ten-year improvement of insulin resistance and growth with recombinant  
494 human insulin-like growth factor 1 in a patient with insulin receptor mutations resulting in  
495 leprechaunism. *Diabetes Metab* **41**, 331-337 (2015).  
496 <https://doi.org/10.1016/j.diabet.2014.11.001>
- 497 39 Weber, D. R., Stanescu, D. E., Semple, R., Holland, C. & Magge, S. N. Continuous subcutaneous  
498 IGF-1 therapy via insulin pump in a patient with Donohue syndrome. *J Pediatr Endocrinol Metab*  
499 **27**, 1237-1241 (2014). <https://doi.org/10.1515/jpem-2013-0402>
- 500 40 Regan, F. M. *et al.* Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF  
501 binding protein-3 complex improves metabolic control in subjects with severe insulin resistance. *J*  
502 *Clin Endocrinol Metab* **95**, 2113-2122 (2010). <https://doi.org/10.1210/jc.2009-2088>
- 503 41 Vestergaard, H., Rossen, M., Urhammer, S. A., Müller, J. & Pedersen, O. Short- and long-term  
504 metabolic effects of recombinant human IGF-I treatment in patients with severe insulin  
505 resistance and diabetes mellitus. *Eur J Endocrinol* **136**, 475-482 (1997).  
506 <https://doi.org/10.1530/eje.0.1360475>
- 507 42 Kuzuya, H. *et al.* Trial of insulinlike growth factor I therapy for patients with extreme insulin  
508 resistance syndromes. *Diabetes* **42**, 696-705 (1993). <https://doi.org/10.2337/diab.42.5.696>
- 509 43 Metwalley, K. A. & Farghaly, H. S. Berardinelli-Seip syndrome type 1 in an Egyptian child. *Indian J*  
510 *Hum Genet* **20**, 75-78 (2014). <https://doi.org/10.4103/0971-6866.132762>
- 511 44 Kirel, B. *et al.* A case of Donohue syndrome "Leprechaunism" with a novel mutation in the insulin  
512 receptor gene. *Turk Pediatri Ars* **52**, 226-230 (2017).  
513 <https://doi.org/10.5152/TurkPediatriArs.2017.3193>
- 514 45 Saito-Hakoda, A. *et al.* A follow-up during puberty in a Japanese girl with type A insulin resistance  
515 due to a novel mutation in INSR. *Clinical pediatric endocrinology : case reports and clinical*  
516 *investigations : official journal of the Japanese Society for Pediatric Endocrinology* **27**, 53-57  
517 (2018). <https://doi.org/10.1297/cpe.27.53>
- 518 46 Kawana, Y., Imai, J., Sawada, S., Yamada, T. & Katagiri, H. Sodium-Glucose Cotransporter 2  
519 Inhibitor Improves Complications of Lipodystrophy: A Case Report. *Ann Intern Med* **166**, 450-451  
520 (2017). <https://doi.org/10.7326/l16-0372>
- 521 47 Hamaguchi, T. *et al.* Treatment of a case of severe insulin resistance as a result of a PIK3R1  
522 mutation with a sodium-glucose cotransporter 2 inhibitor. *Journal of diabetes investigation* **9**,  
523 1224-1227 (2018). <https://doi.org/10.1111/jdi.12825>
- 524 48 Ciudin, A. *et al.* Successful treatment for the Dunnigan-type familial partial lipodystrophy with  
525 Roux-en-Y gastric bypass. *Clin Endocrinol (Oxf)* **75**, 403-404 (2011).  
526 <https://doi.org/10.1111/j.1365-2265.2011.04057.x>
- 527 49 Grundfest-Broniatowski, S., Yan, J., Kroh, M., Kilim, H. & Stephenson, A. Successful Treatment of  
528 an Unusual Case of FPLD2: The Role of Roux-en-Y Gastric Bypass-Case Report and Literature  
529 Review. *J Gastrointest Surg* **21**, 739-743 (2017). <https://doi.org/10.1007/s11605-016-3300-2>
- 530 50 Kozusko, K. *et al.* Clinical and molecular characterization of a novel PLIN1 frameshift mutation  
531 identified in patients with familial partial lipodystrophy. *Diabetes* **64**, 299-310 (2015).  
532 <https://doi.org/10.2337/db14-0104>
- 533 51 Kadowaki, T. *et al.* Two mutant alleles of the insulin receptor gene in a patient with extreme  
534 insulin resistance. *Science* **240**, 787-790 (1988). <https://doi.org/10.1126/science.2834824>
- 535 52 Yoshimasa, Y. *et al.* Insulin-resistant diabetes due to a point mutation that prevents insulin  
536 proreceptor processing. *Science* **240**, 784-787 (1988). <https://doi.org/10.1126/science.3283938>

- 537 53 Shackleton, S. *et al.* LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. *Nat Genet* **24**,  
538 153-156 (2000). <https://doi.org/10.1038/72807>
- 539 54 Lightbourne, M. & Brown, R. J. Genetics of Lipodystrophy. *Endocrinol Metab Clin North Am* **46**,  
540 539-554 (2017). <https://doi.org/10.1016/j.ecl.2017.01.012>
- 541 55 Barroso, I. *et al.* Dominant negative mutations in human PPARgamma associated with severe  
542 insulin resistance, diabetes mellitus and hypertension. *Nature* **402**, 880-883 (1999).  
543 <https://doi.org/10.1038/47254>
- 544 56 Hegele, R. A., Cao, H., Frankowski, C., Mathews, S. T. & Leff, T. PPARG F388L, a transactivation-  
545 deficient mutant, in familial partial lipodystrophy. *Diabetes* **51**, 3586-3590 (2002).  
546 <https://doi.org/10.2337/diabetes.51.12.3586>
- 547 57 Majithia, A. R. *et al.* Prospective functional classification of all possible missense variants in  
548 PPARG. *Nat Genet* **48**, 1570-1575 (2016). <https://doi.org/10.1038/ng.3700>
- 549 58 Mikita, J. S. *et al.* Determining the Suitability of Registries for Embedding Clinical Trials in the  
550 United States: A Project of the Clinical Trials Transformation Initiative. *Ther Innov Regul Sci* **55**, 6-  
551 18 (2021). <https://doi.org/10.1007/s43441-020-00185-5>
- 552 59 Kidwell, K. M. *et al.* Application of Bayesian methods to accelerate rare disease drug  
553 development: scopes and hurdles. *Orphanet J Rare Dis* **17**, 186 (2022).  
554 <https://doi.org/10.1186/s13023-022-02342-5>
- 555 60 Partington, G., Cro, S., Mason, A., Phillips, R. & Cornelius, V. Design and analysis features used in  
556 small population and rare disease trials: A targeted review. *J Clin Epidemiol* **144**, 93-101 (2022).  
557 <https://doi.org/10.1016/j.jclinepi.2021.12.009>
- 558 61 Adams, H. R. *et al.* A novel, hybrid, single- and multi-site clinical trial design for CLN3 disease, an  
559 ultra-rare lysosomal storage disorder. *Clin Trials* **16**, 555-560 (2019).  
560 <https://doi.org/10.1177/1740774519855715>
- 561 62 <<https://www.eclip-web.org/information/registry/>> (  
562 Doherty, D. A. *et al.* Registry randomised trials: a methodological perspective. *BMJ open* **13**,  
563 e068057 (2023). <https://doi.org/10.1136/bmjopen-2022-068057>
- 564 64 James, S., Rao, S. V. & Granger, C. B. Registry-based randomized clinical trials--a new clinical trial  
565 paradigm. *Nat Rev Cardiol* **12**, 312-316 (2015). <https://doi.org/10.1038/nrcardio.2015.33>  
566

567

## Tables

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603


<b>Study types</b>	<b>Number of studies</b>
Case reports	21
Non-randomised experimental study	10
Case series	8
<b>Study Quality*</b>	<b>Number of studies</b>
Good	0
Fair	15
Poor	28
<b>Phenotypes</b>	<b>Number of participants</b>
Partial lipodystrophy	90 (72 <i>LMNA</i> , 15 <i>PPARG</i> , 2 <i>PLIN1</i> , 1 <i>PIK3R1</i> )
Generalised lipodystrophy	56 (21 <i>AGPAT2</i> , 21 <i>BSCL2</i> , 1 <i>PTRF</i> , 2 <i>LMNA</i> )
Insulin receptor	17 (7 Monoallelic, 10 Biallelic)
<b>Intervention</b>	<b>Number of participants</b>
Metreleptin	111 (71/40/0)
rhIGF-1 or rhIGF-1/IGFBP3 composite	15 (0/0/15)
Thiazolidinedione	13 (12/1/0)
Metformin	5 (2/1/2)
Bariatric surgery	4 (4/0/0)
SGLT2i	2 (1/1/0)

**Table 1: Summary characteristics of included studies.**

\*Based on NHLBI quality assessment tool; #Numbers in brackets are for partial lipodystrophy/generalised lipodystrophy/ insulin receptor individuals respectively. Abbreviations: rhIGF-1, recombinant human insulin-like growth factor 1; IGFBP3, insulin-like growth factor binding protein 3; SGLT2i, sodium-glucose co-transporter-2 inhibitor

604  
605  
606  
607  
608


## Figures



609  
610  
611  
612  
613

**Figure 1:** Flow diagram of publications evaluated based on the search strategy.

614  
615  
616  
617  
618



619  
620

621 **Figure 2: Effects of metreleptin in monogenic forms of lipodystrophy** Least square mean  
622 change in (A) Hemoglobin A1c (A1c), (B)  $\log_{10}$  serum triglyceride concentration and (C) Body  
623 Mass Index (BMI) in patients with partial lipodystrophy, generalized lipodystrophy, all forms  
624 of lipodystrophy, and subgroups with *PPARG*, *LMNA*, *BSC1.2*, and *AGPAT2* mutations.

625


626

627

628

629

630




631

632 **Figure 3: Effects of recombinant human Insulin-like Growth Factor-1 (rhIGF) alone or in**  
633 **combination with Insulin-like Growth Factor Binding Protein-3 (IGFBP3) in patients**  
634 **with *INSR* mutations** Least square mean change in hemoglobin A1c (A1c), in all patients  
635 with *INSR* mutations, and in subgroups with biallelic and monoallelic mutations.



636

637



638

639 **Figure 4: Effects of thiazolidinediones in monogenic forms of lipodystrophy** Least

640 square mean change in (A) Hemoglobin A1c (A1c), (B) Log<sub>10</sub> serum triglyceride

641 concentration and (C) Body Mass Index (BMI) in patients with partial lipodystrophy,

642 generalized lipodystrophy, all forms of lipodystrophy, and subgroups with *PPARG*, and

643 *LMNA* mutations.

644

### Supplemental Tables

645

Disease	Gene Names and Variants	Treatments
Lipodystrophy	<i>LMNA</i>	Medication
Severe Insulin resistance	Lamin A/C	Therapy
Type A insulin resistance	<i>BSCL2</i>	Medical management
Donohue syndrome	Seipin	Treatment
Rabson Mendenhall syndrome	<i>AGPAT2</i>	SGLT2 inhibitor
Leprechaun	<i>PTRF</i>	SGLT2i
Leprechaunism	<i>CAVIN1</i>	SGLT-2 inhibitor
FPLD	<i>CAV1</i>	SGLT-2i
FPLD2	<i>ZMPSTE24</i>	Sodium Glucose Transporter 2 inhibitor
FPLD3	<i>PPARG</i>	Dapagliflozin
FPLD4	<i>PLIN1</i>	Empagliflozin
FPLD5	<i>MFN2</i>	Ertagliflozin
FPLD6	<i>CIDEA</i>	Canagliflozin
FPLD7	<i>LIPE</i>	Flozin
SHORT syndrome	<i>PCYT1A</i>	Thiazolidinedione
SOFT syndrome	<i>INSR</i>	PPARγ Agonist
vSOFT	<i>AKT2</i>	PPAR gamma agonist
Werner syndrome	<i>PIK3R1</i>	TZD
Bloom syndrome	<i>AKT2</i>	Rosiglitazone
MOPDII	<i>WRN</i>	Pioglitazone
Osteodysplastic primordial dwarfism of Majewski type 2	<i>BLM</i>	Troglitazone
Alstrom syndrome	<i>NSMCE2</i>	GLP1RA
MANDIBULAR HYPOPLASIA, DEAFNESS, PROGEROID FEATURES, AND LIPODYSTROPHY SYNDROME	<i>POLD1</i>	GLP1 Receptor Agonists
MDPL	<i>PCNT</i>	GLP-1 Receptor Agonists
Mandibuloacral dysplasia	<i>POC1A</i>	GLP-1RA
MARFANOID-PROGEROID-LIPODYSTROPHY SYNDROME	<i>ALMS1</i>	Exenatide
MFLS	<i>PSMB8</i>	Liraglutide
PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME 1	<i>FBN1</i>	Lixisenatide
PRAAS1		Semaglutide
		Dulaglutide
		Albiglutide
		Bariatric surgery
		Obesity Surgery
		Weight reduction surgery

	gastric band
	Roux-en-Y
	Gastric sleeve
	Gastric bypass
	metabolic surgery
	IGF-1
	rhIGF-1
	somatokine
	recombinant human insulin like growth factor 1
	Insulin like growth factor 1
	Increlex
	Mecasermin
	IGF-1/IGFBP3
	IGF1
	rhIGF1
	IGF1/IGFBP3
	leptin
	rhleptin
	metreleptin
	Myalept
	Myalepta

646  
647  
648  
649

**Supplemental Table 1: Descriptors of diseases, gene names and treatments included in the initial search**

650

651

652

653

654



Supplemental Table  
2 Quality assessmen

655

656

657

658

**Supplemental Table 2: Detailed Quality Assessment of Included Studies**

659

		Treatment						Total
		rhIGF-1 or rhIGF-1/IGFBP3 composite	SGLT2i	TZD	Bariatric surgery	Metformin	Metreleptin	
Gene	<i>AGPAT2</i>	0	0	0	0	1	20	21
	<i>BSC2</i>	0	1	1	0	0	19	21
	<i>PTRF</i>	0	0	0	0	0	1	1
	<i>LMNA</i> ( <i>progeroid</i> )	0	0	0	0	0	2	2
	<i>LMNA</i> ( <i>FPL</i> )	0	0	9	2	2	59	72
	<i>PPARG</i>	0	0	5	0	0	10	15
	<i>PLIN1</i>	0	0	0	2	0	0	2
	<i>PIK3R1</i>	0	1	0	0	0	0	1
	<i>INSR</i>	15	0	0	0	2	0	17
<i>All partial LD</i>		--	1	14	4	2	71	90
<i>All generalised LD</i>		--	1	1	0	1	40	43
<i>All LD</i>		--	2	15	4	3	111	135

660

661 **Supplemental Table 3: Number of individuals by intervention and genotype in included**

662 **studies** Abbreviations: rhIGF-1, recombinant human insulin-like growth factor 1; IGFBP3,

663 insulin-like growth factor binding protein 3; SGLT2i, sodium-glucose co-transporter-2

664 inhibitor; TZD, thiazolidinedione; FPL = Familial Partial Lipodystrophy

665  
666  
667  
668  
669  
670  
671



Supplemental Table  
4 Summary stats 14 /

672  
673  
674  
675


**Supplemental Table 4: Summary statistics of extracted data**

676

### Supplemental Figures

677

678



679

680

681


Supplemental Figure 1: Effects of Metreleptin therapy on glycated

682

haemoglobin (A1c) by genotype

683

684  
685  
686  
687




688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698

**Supplemental Figure 2: Effects of Metreleptin therapy on serum triglyceride concentration by genotype**




699  
700  
701  
702  
703  
704



705  
706  
707  
708  
709  
710  
711  
712

**Supplemental Figure 3: Effects of Metreleptin therapy on body mass index (BMI) by genotype**


713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729



730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750

**Supplemental Figure 4: Effects of recombinant IGF-1 or IGF-1 plus IGFBP3 therapy on glycated haemoglobin (A1c) in monallelic and biallelic insulin receptoropathy**


751  
752  
753  
754  
755  
756



757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770

Supplemental Figure 5: Effects of thiazolidinedione therapy by genotype





771  
772  
773  
774  
775



776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789

Supplemental Figure 6: Effects of bariatric surgery by genotype


790  
791  
792  
793  
794



795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807

**Supplemental Figure 7: Effects of metformin therapy by genotype**

808  
809  
810  
811  
812  
813



814  
815  
816  
817

Supplemental Figure 8: Effects of SGLT2 inhibitor therapy by genotype